Assistant Lecture

Office: Room 1001A, 10/F, School of Medical and Health Sciences, Ma Kam Chan Memorial Building, 31 Wylie Road, Homantin, Kowloon, Hong Kong
Tel: (852) 3859 5916
Email: mhhuang@twc.edu.hk

Biography:
Dr. Huang joined Tung Wah College in 2025 as an Assistant Lecturer at the School of Medical and Health Sciences. She brings with her a multidisciplinary background in pharmacy, bioinformatics, and oncology research. Prior to joining TWC, she served as a Clinical Pharmacist in mainland China and was involved in patient-centered pharmaceutical care and clinical drug management.

Dr. Huang earned her PhD in Health Technology and Informatics from The Hong Kong Polytechnic University, with a research focus on tumor hypoxia, immune checkpoint inhibitor resistance, and AI-driven personalized therapy in hepatocellular carcinoma. She has extensive experience in big data analysis, radiomics, and the development of prognostic and predictive models integrating genomic and imaging data.

She has published 14 papers in international peer-reviewed journals and presented 2 research studies at the American Society of Clinical Oncology (ASCO) conference.

Education:
PhD in Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong SAR
Master of Science in Pharmacy, Guilin Medical University, China
Bachelor of Science in Pharmacy, Jinzhou Medical University, China
Professional Qualifications / Memberships:
Associate Chief Pharmacist in Mainland China

Teaching Areas:
Pharmacology, clinical pharmacy, cancer biology, physiology, bioinformatics, health technology

Research Interests:
Tumor immunotherapy
Hypoxia-related mechanisms
Bioinformatics, radiogenomics
AI-based prediction models
Personalized medicine
Drug resistance
 

Publications:

a) Representative Publications:

1. Huang MH, Lan T, Chen XY, Chen R, Ding X, Tai CS, Wong SC, Chan WC. 2025. Functional role of NOXA in hypoxia-mediated PD-L1 inhibitor response in hepatocellular carcinoma. Int J Mol Sci. 26(10):4766. https://doi.org/10.3390/ijms26104766 (IF= 4.9)
2.  Huang MH, Chen XY, Jiang Y, Chan WC. 2025. Kolmogorov–Arnold network model integrated with hypoxia risk for predicting PD-L1 inhibitor responses in hepatocellular carcinoma. Bioengineering. 12(3):322. https://doi.org/10.3390/bioengineering12030322 (IF= 3.8)
3.  Ng KY, Chen XY, Huang MH, Kong LY, Cheung KT, Chan WC. 2025. Integrated clinical-radiomic model for predicting treatment response of concurrent chemo-radiotherapy and radiotherapy alone in controversial subgroup of AJCC/UICC ninth edition stage I nasopharyngeal cancer. Chin J Cancer Res. 37(2):119–137. https://doi.org/10.21147/j.issn.1000-9604.2025.02.01 (IF= 7)
4.  Huang MH, Yang SJ, Tai CS, Zhang LF, Zhou YN, Cho CS, Chan WC, Wong SC. 2023. Bioinformatics identification of regulatory genes and mechanism related to hypoxia-induced PD-L1 inhibitor resistance in hepatocellular carcinoma. Int J Mol Sci. 24(10). https://doi.org/10.3390/ijms24108543 (IF= 4.9)
5.  Lun HM, Huang MH, Zhao YH, Huang JY, Li LL, Cheng HY, Leung Y, So HW, Wong YC, Cheung CK, Chan WC, Hu Q. 2024. Contrast-enhanced ultrasound-based radiomics for the prediction of axillary lymph nodes status in breast cancer. Cancer Rep. 7:e70011. https://doi.org/10.1002/cnr2.70011 (IF= 1.5)
6.  Kong LY, Huang MH, Zhang LF, Chan WC. 2024. Enhancing diagnostic images to improve the performance of the Segment Anything Model in medical image segmentation. Bioengineering. 11(3). https://doi.org/10.3390/bioengineering11030233 (IF= 3.8)
7.  Chan WC, Wong SC, Cho CS, Huang MH, Zhang F, Chui ML, Lai NY, Chan YK, Cheung HC, Cheung CY, Tang KF, Tse ML, Wong HK, Kwok MF, Shen XP, Zhang SL, Chiu WH. 2022. Primary tumor radiomic model for identifying extrahepatic metastasis of hepatocellular carcinoma based on contrast enhanced computed tomography. Diagnostics. 13(1). https://doi.org/10.3390/diagnostics13010017 (IF= 3)
8.  Chan WC, Ding T, Shao HL, Huang MH, Hui FY, Cho CS, Wong SC, Tong KW, Chiu WH, Huang LY, Zhou HY. 2022. Augmented features synergize radiomics in post-operative survival prediction and adjuvant therapy recommendation for non-small cell lung cancer. Front Oncol. 12. https://doi.org/10.3389/fonc.2022.860238 (IF= 3.64)
9.  Huang MH, Kong B, Meng JY, Lv YB, Peng YF, Chen YP, Tan XD. 2020. Discovery of novel N-aryl pyrrothine derivatives as bacterial RNA polymerase inhibitors. Chem Biol Drug Des. 96(5):1262–1271. https://doi.org/10.1111/cbdd.13736 (IF= 3.2)
10.  Tan XD, Huang MH, Nian SY, Peng YF, Qin JL, Kong B, Duan XQ. 2020. Design, synthesis and biological evaluation of novel hybrids of N-arylpyrrothine-base α-pyrone as bacterial RNA polymerase inhibitors. Bioorg Med Chem Lett. 30(11):127146. https://doi.org/10.1016/j.bmcl.2020.127146 (IF= 2.5)
11.  Nian SY, Wang GP, Jiang ZL, Xiao Y, Huang MH, Zhou YH, Tan XD. 2019. Synthesis and biological evaluation of novel SIPI-7623 derivatives as farnesoid X receptor (FXR) antagonists. Mol Divers. 23:19–33. https://doi.org/10.1007/s11030-018-9843-2 (IF= 3.8)
12.  Nian SY, Yu ZP, Tan XD, Gan X, Huang MH, Zhou YH, Wang GP. 2018. Synthesis and biological evaluation of N-(5-(2,5-dimethyl-phenoxy)-2,2-dimethylpentyl)-benzamide derivatives as novel farnesoid X receptor (FXR) antagonists. Lett Drug Des Discov. 15(9):923–936. https://doi.org/10.2174/1570180815666171226150403 (IF= 1.2)

b) Conference Publication

1. Huang MH, Chan WC. 2024. Machine learning identification of hypoxia-related genes and prognostic risk-scoring model for effective survival stratification in hepatocellular carcinoma. American Society of Clinical Oncology (ASCO). 42, e16261–e16261. https://doi.org/10.1200/JCO.2024.42.16_suppl.e16261
2. Huang MH, Chan WC. 2023. Hypoxia-related genes and PD-L1 inhibitor resistance in hepatocellular carcinoma. American Society of Clinical Oncology (ASCO) Breakthrough. 9, 158–158. https://doi.org/10.1200/GO.2023.9.Supplement_1.158

Research Projects:

2025 - Present: College Research Grant (CRG)
Evaluation of JNK and hypoxia related signaling pathways on the prognosis of colorectal cancer – A genomic approach (Co-investigator)